Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
New GSK CEO Emma Walmsley is going for it in oncology.
Looking to steer the pharma giant back toward a pipeline that can stir …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
